The John Rankin Laboratory of Pulmonary Medicine, Departments of Population Health Sciences and of Orthopedics and Rehabilitation, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin 53706, USA.
Physiol Rev. 2010 Jan;90(1):47-112. doi: 10.1152/physrev.00043.2008.
Sleep-induced apnea and disordered breathing refers to intermittent, cyclical cessations or reductions of airflow, with or without obstructions of the upper airway (OSA). In the presence of an anatomically compromised, collapsible airway, the sleep-induced loss of compensatory tonic input to the upper airway dilator muscle motor neurons leads to collapse of the pharyngeal airway. In turn, the ability of the sleeping subject to compensate for this airway obstruction will determine the degree of cycling of these events. Several of the classic neurotransmitters and a growing list of neuromodulators have now been identified that contribute to neurochemical regulation of pharyngeal motor neuron activity and airway patency. Limited progress has been made in developing pharmacotherapies with acceptable specificity for the treatment of sleep-induced airway obstruction. We review three types of major long-term sequelae to severe OSA that have been assessed in humans through use of continuous positive airway pressure (CPAP) treatment and in animal models via long-term intermittent hypoxemia (IH): 1) cardiovascular. The evidence is strongest to support daytime systemic hypertension as a consequence of severe OSA, with less conclusive effects on pulmonary hypertension, stroke, coronary artery disease, and cardiac arrhythmias. The underlying mechanisms mediating hypertension include enhanced chemoreceptor sensitivity causing excessive daytime sympathetic vasoconstrictor activity, combined with overproduction of superoxide ion and inflammatory effects on resistance vessels. 2) Insulin sensitivity and homeostasis of glucose regulation are negatively impacted by both intermittent hypoxemia and sleep disruption, but whether these influences of OSA are sufficient, independent of obesity, to contribute significantly to the "metabolic syndrome" remains unsettled. 3) Neurocognitive effects include daytime sleepiness and impaired memory and concentration. These effects reflect hypoxic-induced "neural injury." We discuss future research into understanding the pathophysiology of sleep apnea as a basis for uncovering newer forms of treatment of both the ventilatory disorder and its multiple sequelae.
睡眠呼吸暂停和呼吸紊乱是指间歇性、周期性的气流停止或减少,伴有或不伴有上呼吸道阻塞(OSA)。在解剖结构受损、易塌陷的气道中,睡眠时对上气道扩张肌运动神经元的代偿性紧张性传入丧失会导致咽气道塌陷。反过来,睡眠者补偿这种气道阻塞的能力将决定这些事件的周期性程度。现在已经确定了几种经典神经递质和越来越多的神经调质,它们有助于对上气道运动神经元活动和气道通畅性的神经化学调节。在开发具有可接受的特异性的药物治疗方面,用于治疗睡眠呼吸暂停所致气道阻塞的进展有限。我们综述了三种主要的长期后遗症,这些后遗症已通过使用持续气道正压通气(CPAP)治疗在人类中进行了评估,并通过长期间歇性低氧血症(IH)在动物模型中进行了评估:1)心血管。有强有力的证据支持严重 OSA 导致日间系统性高血压,对肺动脉高压、中风、冠心病和心律失常的影响则不太确定。介导高血压的潜在机制包括增强化学感受器敏感性导致日间交感血管收缩活性过度,以及超氧化物离子的过度产生和对阻力血管的炎症作用。2)胰岛素敏感性和葡萄糖调节的稳态受到间歇性低氧和睡眠中断的负面影响,但 OSA 的这些影响是否足以独立于肥胖症对“代谢综合征”产生重大影响仍未确定。3)神经认知效应包括日间嗜睡和记忆力及注意力受损。这些影响反映了缺氧诱导的“神经损伤”。我们讨论了未来对睡眠呼吸暂停病理生理学的研究,作为揭示治疗通气障碍及其多种后遗症的新方法的基础。